File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
  • Find via Find It@HKUL
Supplementary

Conference Paper: Rifaximin for the treatment of functional dyspepsia: a double-blind randomized placebo-controlled trial

TitleRifaximin for the treatment of functional dyspepsia: a double-blind randomized placebo-controlled trial
Authors
KeywordsMedical sciences
Gastroenterology
Issue Date2015
PublisherWB Saunders Co. The Journal's web site is located at http://www.elsevier.com/locate/gastro
Citation
The 2015 Digestive Disease Week (DDW 2015), Washington, DC., 16-19 May 2015. In Gastroenterology, 2015, v. 148 n. 4 suppl. 1, p. S49, abstract no. 195 How to Cite?
AbstractBACKGROUND: Patients with functional dyspepsia (FD) frequently present with bloating and belching. Rifaximin has been shown to be effective in treatment of non-constipated irritable bowel syndrome (IBS). Individual symptom analyses also showed that there was significant reduction of bloating symptoms with rifaximin. We performed a pilot double-blinded, randomized, placebo-controlled trial to evaluate the effects of rifaximin as a treatment for FD. METHODS: Patients who had FD as per the ROME III criteria were randomized to receive either rifaximin 400mg TDS or identical looking placebo TDS for two weeks. We excluded patients with predominant symptoms more suggestive of IBS. All patients had normal upper endoscopy and were negative for H. pylori on entry of study. Subjects were assessed at 2, 4 and 8 weeks for symptoms. The primary end point was the proportion of patients who had adequate relief of global dyspepsia symptoms (GDS) at week 4. Adequate relief was defined as self-reported GDS of 'nil to mild' symptoms as measured on a 4-point scale (nil, mild, moderate or severe). Other secondary end points included the proportion of patients who had adequate relief of GDS at week 8, and other FD-related symptoms (bloating, belching, abdominal pain, epigastric pain, flatulence, nausea and vomiting) at week 4. Analysis was based on intention-to-treat. RESULTS: A total of 81 patients were included in the study: 39 were randomised to rifaximin. 61 (75.3%) were female and the mean age was 53.5 (±12.8) years. The two groups were comparable in all baseline characteristics including GDS and other FD-related symptoms. At week 4, 33.3% of the rifaximin group and 58.8% of placebo groups still had 'moderate-to-severe' GDS, respectively (P=0.036; Figure 1). The relative risk (RR) for 'moderate-to-severe' GDS in the rifaximin group at week 4 was 0.60 (95% Confidence Interval (CI) 0.37-0.98). For bloating symptoms at week 4, 23.1% of the rifaximin group and 54.8% of the placebo group still experienced 'moderate-to-severe' symptoms (RR for rifaximin group = 0.44; 95% CI 0.21 to 0.93; P=0.02). There was also a trend favoring rifaximin for belching symptoms (19.2% vs. 42.4% in placebo group experiencing 'moderate-to-severe' symptoms; P=0.058). There was no significant difference between the two groups in other FD symptoms including pain, nausea and vomiting and flatulence. The rates of adverse events of the rifaximin and placebo groups were comparable (10.1% Vs. 17.7%, P=0.20). CONCLUSIONS: The results of this pilot study demonstrate that rifaximin is effective in the treatment of FD, particularly in the relief of GDS and bloating symptoms. A large scale randomized controlled trial should be considered.
Persistent Identifierhttp://hdl.handle.net/10722/217547
ISSN
2015 Impact Factor: 18.187
2015 SCImago Journal Rankings: 7.170

 

DC FieldValueLanguage
dc.contributor.authorTan, VPY-
dc.contributor.authorLiu, SHK-
dc.contributor.authorLam, YF-
dc.contributor.authorHung, IFN-
dc.contributor.authorLeung, WK-
dc.date.accessioned2015-09-18T06:03:59Z-
dc.date.available2015-09-18T06:03:59Z-
dc.date.issued2015-
dc.identifier.citationThe 2015 Digestive Disease Week (DDW 2015), Washington, DC., 16-19 May 2015. In Gastroenterology, 2015, v. 148 n. 4 suppl. 1, p. S49, abstract no. 195-
dc.identifier.issn0016-5085-
dc.identifier.urihttp://hdl.handle.net/10722/217547-
dc.description.abstractBACKGROUND: Patients with functional dyspepsia (FD) frequently present with bloating and belching. Rifaximin has been shown to be effective in treatment of non-constipated irritable bowel syndrome (IBS). Individual symptom analyses also showed that there was significant reduction of bloating symptoms with rifaximin. We performed a pilot double-blinded, randomized, placebo-controlled trial to evaluate the effects of rifaximin as a treatment for FD. METHODS: Patients who had FD as per the ROME III criteria were randomized to receive either rifaximin 400mg TDS or identical looking placebo TDS for two weeks. We excluded patients with predominant symptoms more suggestive of IBS. All patients had normal upper endoscopy and were negative for H. pylori on entry of study. Subjects were assessed at 2, 4 and 8 weeks for symptoms. The primary end point was the proportion of patients who had adequate relief of global dyspepsia symptoms (GDS) at week 4. Adequate relief was defined as self-reported GDS of 'nil to mild' symptoms as measured on a 4-point scale (nil, mild, moderate or severe). Other secondary end points included the proportion of patients who had adequate relief of GDS at week 8, and other FD-related symptoms (bloating, belching, abdominal pain, epigastric pain, flatulence, nausea and vomiting) at week 4. Analysis was based on intention-to-treat. RESULTS: A total of 81 patients were included in the study: 39 were randomised to rifaximin. 61 (75.3%) were female and the mean age was 53.5 (±12.8) years. The two groups were comparable in all baseline characteristics including GDS and other FD-related symptoms. At week 4, 33.3% of the rifaximin group and 58.8% of placebo groups still had 'moderate-to-severe' GDS, respectively (P=0.036; Figure 1). The relative risk (RR) for 'moderate-to-severe' GDS in the rifaximin group at week 4 was 0.60 (95% Confidence Interval (CI) 0.37-0.98). For bloating symptoms at week 4, 23.1% of the rifaximin group and 54.8% of the placebo group still experienced 'moderate-to-severe' symptoms (RR for rifaximin group = 0.44; 95% CI 0.21 to 0.93; P=0.02). There was also a trend favoring rifaximin for belching symptoms (19.2% vs. 42.4% in placebo group experiencing 'moderate-to-severe' symptoms; P=0.058). There was no significant difference between the two groups in other FD symptoms including pain, nausea and vomiting and flatulence. The rates of adverse events of the rifaximin and placebo groups were comparable (10.1% Vs. 17.7%, P=0.20). CONCLUSIONS: The results of this pilot study demonstrate that rifaximin is effective in the treatment of FD, particularly in the relief of GDS and bloating symptoms. A large scale randomized controlled trial should be considered.-
dc.languageeng-
dc.publisherWB Saunders Co. The Journal's web site is located at http://www.elsevier.com/locate/gastro-
dc.relation.ispartofGastroenterology-
dc.rights© <year>. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/-
dc.subjectMedical sciences-
dc.subjectGastroenterology-
dc.titleRifaximin for the treatment of functional dyspepsia: a double-blind randomized placebo-controlled trial-
dc.typeConference_Paper-
dc.identifier.emailTan, VPY: vpytan@hku.hk-
dc.identifier.emailLiu, SHK: drkliu@hku.hk-
dc.identifier.emailLam, YF: fyflam@hku.hk-
dc.identifier.emailHung, IFN: ivanhung@hkucc.hku.hk-
dc.identifier.emailLeung, WK: waikleung@hku.hk-
dc.identifier.authorityTan, VPY=rp01458-
dc.identifier.authorityHung, IFN=rp00508-
dc.identifier.authorityLeung, WK=rp01479-
dc.identifier.hkuros254313-
dc.identifier.volume148-
dc.identifier.issue4, suppl. 1-
dc.identifier.spageS49, abstract no. 195-
dc.identifier.epageS49, abstract no. 195-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats